Radioiodine for Breast Cancer Therapy : A pilot Project in SKBR-3 Cell Line
Miftah Irrahmah 1, Yulia Kurniawati2, V.Y.Susilo3, S.Setiyowati3, Aisyah Elliyanti 1,2
1. Department of Medical physic, Faculty of Medicine, Universitas Andalas
2. Department of Radiology, Faculty of Medicine, Universitas Andalas
3. Center of Radioisotopes and Radiopharmaceuticals Technology, National Nuclear Energy Agency,Kawasan Puspiptek Serpong,Indonesia
Corresponding Author: Aisyah Elliyanti
Email: aelliyanti[at]med.unand.ac.id
Abstract
Background: Radioiodine has been known as an adjuvant therapy for thyroid cancer. Beside thyroid, radioiodine is taken up by breast tissue. So, radioiodine is expected can be as an alternative for breast cancer therapy. The aim of this study was to analyze uptake and toxicity of radioiodine in the SKBR-3 cell line. Material and Method: This study used SKBR-3 cell line that represent a HER2 type of breast cancer. Cells were planted in DMEM medium added 10% fetal bovine serum (FBS), panstrep 1% and amphotericin B. Cells were grown until 80% confluent and then stripped. Subsequently the cells were sub-cultured on plates 12 and 6 wells respectively for measured uptake and toxicity of radioiodine. Radioiodine uptake was calculated by sum efflux of 125 Iodine (125I) and the amount of uptake after the addition of 95% ethanol. Radioiodine toxicity was measured by calculated the 131Iodine (131I) effect to cell proliferation using clonogenic assay. Results: Radioiodine was taken up by SKBR3 cells and the average of uptake was 194 ± 50 cpm/106 cell. Radioiodine showed reducing of cell proliferation. The average cell proliferation after 131I exposure was 47 ± 6%. Conclusion: Radioiodine is taken by SKBR3 cells and it demonstrate the toxicity to the cell. Our finding shows an opportunity for radioiodine as an alternative for breast cancer therapy. Further study is need to understand the mechanism.
Keywords: Radioiodine, SKBR3 cell line, breast cancer
Topic: Health Technology and Medical Treatment